Table 1 Laboratory parameters before treatment with tocilizumab (TCZ), after 6 months and after 12 months from starting TCZ (WBC = White blood cell count; N = Neutrophils; L = Lymphocyte count; Hb = Hemoglobin; PLT = platelet count; CRP = C reactive protein; SLEDAI = Systemic Lupus Erythematosus disease activity index); NA = not available.
Baseline | 72 h after TCZ | 1 month after TCZ | 6 months after TCZ | 12 months after TCZ | Normal value | |
|---|---|---|---|---|---|---|
WBC (x109/L) | 4.0 | 9.91 | 5.4 | 4.2 | 4.4 | 4.0-13.5 |
N (x109/L) | 2.0 | 5.41 | 2.4 | 1.42 | 1.7 | 1.3–7.9 |
L (x109/L) | 1.5 | 3.73 | 2.5 | 2.2 | 2.25 | 1.0-6.5 |
Hb (g/dL) | 11.2 | 12.5 | 13.7 | 12.5 | 12.9 | 13.0–16.0 |
PLT (x109/L) | 259 | 219 | 109 | 208 | 191 | 150–450 |
CRP (mg/dL) | 0.6 | < 0.03 | 0.03 | 0.03 | 0.03 | < 0.5 |
IgG (g/L) | 22.31 | 8.09 | 6.16 | 6.98 | 5.50–15.80 | |
C3 (g/L) | 0.36 | 0.57 | 0.71 | 0.67 | 0.75 | 0.90–1.80 |
C4 (g/L) | 0.02 | 0.03 | 0.05 | 0.07 | 0.14 | 0.10–0.40 |
Anti-dsDNA antibody score titer | 1:640 | NA | 1:20 | 1:10 | 1:10 | < 1:10 |
Anti-Sm antibody (U/mL) | 14480.0 | NA | 1589.0 | 496.0 | 428.0 | < 5.0 |
Anti-U1RNP IgG antibody (U/mL) | 370.0 | NA | 245 | 145.0 | 111.0 | < 7.0 |
SLEDAI | 14 | 6 | 2 | 2 | 2 | ≤ 4 |